RxDoctor Payments Data

Sean di Cristofaro, MD

Family Practice · Hurricane, WVNPI 1053370056

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 459 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,959 and has fallen 64.0% since, to $705 in 2025. Among family practice clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,433in general payments, 2019–2025

Across 459 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Amgen$657
  • Novo Nordisk$570
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$396
  • GSK$373
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$7,417100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,433 in reported general payments places this provider in the 95th percentile of 96 family practice providers in West Virginia.

See all family practice providers in West Virginia

Medicare billing

Part B allowed, 2024
$60,500
Medicare patients
169
Services billed
2,452

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide128$165,218
OzempicSemaglutide68$104,306
Tresiba Flextouch U-200Insulin Degludec64$96,207
EliquisApixaban76$77,179
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog50$70,594
XareltoRivaroxaban45$48,594
JardianceEmpagliflozin43$46,503
FarxigaDapagliflozin Propanediol47$44,053
VascepaIcosapent Ethyl53$40,697
LinzessLinaclotide41$37,499
TrulicityDulaglutide21$35,763
JanuviaSitagliptin Phosphate29$33,169
RybelsusSemaglutide12$31,270
VraylarCariprazine Hcl11$27,136
TradjentaLinagliptin35$26,560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$153$200,981149 claims
Novo NordiskOzempic, Rybelsus$570$135,57680 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$45$87,330101 claims
PfizerEliquis$204$77,17976 claims
AbbVieLinzess, Vraylar, Creon$1,537$77,09466 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,429$75,01792 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$373$55,25368 claims
Johnson & JohnsonXarelto$81$48,59445 claims
MerckJanuvia, Belsomra, Lagevrio (Eua)$130$46,55459 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 96 family practice providers in West Virginia.

Other family practice in Hurricane

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →